WO2024236538 - AZETIDINE LINKED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS
National phase entry:
Publication Number
WO/2024/236538
Publication Date
21.11.2024
International Application No.
PCT/IB2024/054799
International Filing Date
17.05.2024
Title **
[English]
AZETIDINE LINKED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS
[French]
COMPOSÉS HÉTÉROCYCLYLE BICYCLIQUES LIÉS À L'AZÉTIDINE EN TANT QUE MODULATEURS DE CCR4
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
ABBINENI, Chandrasekhar
SAMAJDAR, Susanta
TALLURI, Krishna Chaitanya
MUKHERJEE, Subhendu
MIDUTURU, Chandrasekhar V
Priority Data
202341034417
17.05.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3279 | |
| EPO | Filing, Examination, Granting | 23778 | |
| Japan | Filing, Examination, Granting | 3024 | |
| South Korea | Filing, Examination, Granting | 3639 | |
| USA | Filing, Examination, Granting | 17540 |
Total:
51,260
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides azetidine linked bicyclic heterocyclyl compounds of formula (I-1), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the modulation of CCR4 activity. Compounds of the present disclosure are especially useful for treating cancer and inflammatory diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I-1) or a pharmaceutically acceptable salt or a stereoisomer thereof.[French]
La présente divulgation concerne des composés hétérocyclyle bicycliques liés à l'azétidine de formule (I-1), qui sont thérapeutiquement utiles en tant que modulateurs de CCR4. Ces composés sont utiles dans le traitement et/ou la prévention de maladies et/ou de troubles sensibles à la modulation de l'activité de CCR4. Les composés selon la présente divulgation sont particulièrement utiles pour le traitement du cancer et de maladies et de troubles inflammatoires. La présente divulgation concerne également des procédés de préparation des composés et des formulations pharmaceutiques comprenant au moins l'un des composés de formule (I-1) ou un sel ou un stéréoisomère pharmaceutiquement acceptable de ceux-ci.